Therapie der Osteoporose beim geriatrischen Patienten

Gosch, M.; Kammerlander, Christian; Pils, Katharina; Lechleitner, Monika; Benvenuti-Falger, Ursula; Roth, Tobias; Joosten-Gstrein, B.; Pietschmann, Péter

doi:10.1007/s00391-012-0336-0

Cited by 5 publications

(2 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Gerade für geriatrische Patienten liegen sehr gute Daten zur Frakturprävention vor [22]. Die Dosis beträgt 2 g täg-lich abends mit einem Glas Wasser.…”

Section: Strontiumranelatunclassified

See 1 more Smart Citation

Osteoporose – Therapie und sektorenübergreifendes Management

Mikosch

Gosch

2013

Wien Med Wochenschr

View full text Add to dashboard Cite

Osteoporosis is defined as a systemic bone disorder with decreased bone strength and an increased susceptibility for fragility fractures. In particular elderly people face an increased fracture risk. Fracture stabilisation by different methods of osteosynthesis and fast remobilisation has become standard procedures after a fragility fracture due to osteoporosis. However, only a small group of patients receive osteoporosis drug therapy with the aim to reduce the rate of further fractures. In literature this has been described as "osteoporosis care gap". In the past, various projects have been performed in order to overcome this problem of osteoporosis care after fragility fractures. The article presents the current problems in daily routine concerning the initiation of an osteoporosis therapy after a fracture. A simple concept of necessary procedures and questions is presented as a possible solution for the interface management of osteoporosis drug therapy after fragility fractures. In addition, current osteoporosis therapies are presented in the view of care for geriatric patients.

show abstract

“…Gerade für geriatrische Patienten liegen sehr gute Daten zur Frakturprävention vor [22]. Die Dosis beträgt 2 g täg-lich abends mit einem Glas Wasser.…”

Section: Strontiumranelatunclassified

“…Für Teriparatide liegen positive Daten zur Frakturprä-vention auch bei Patienten über 75 Jahre vor [22]. Für beide Substanzen gilt eine eingeschränkte Nierenfunktion (Creatinin-Clearence < 30 ml/min) als Kontraindiaktion, Teriparatid hat die Zulassung für Frauen und Männer, PTH 1-84 nur für Frauen.…”

Section: Pth (1-84) Und Teriparatideunclassified

Osteoporose – Therapie und sektorenübergreifendes Management

Mikosch

Gosch

2013

Wien Med Wochenschr

View full text Add to dashboard Cite

show abstract

Management der Osteoporose nach Fragilitätsfrakturen

et al. 2018

View full text Add to dashboard Cite

Osteoporosis is defined as a systemic bone disease with decreased bone strength and an increased susceptibility for fractures. Older people in particular face an increased risk of fractures. These kind of fractures are usually caused by an inadequate trauma and are the so-called fragility fractures. In older adults immediate fracture stabilization and early mobilization have become the standard procedure after a fragility fracture. Treatment of the underlying osteoporosis often plays a minor role in clinical practice. Only a small group of patients are already under osteoporosis medication and even after a fracture occurs only few patients receive osteoporosis drug treatment with the aim to reduce the progression of osteoporosis and to reduce subsequent fractures. In the literature this has been described as the osteoporosis care gap. The following article presents an overview of treatment options and answers many different questions from the clinical routine.

show abstract